Article info
PDFSystemic sclerosis
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
- Correspondence to Dr James R Seibold, Scleroderma Research Consultants, LLC, Aiken, SC 29803, USA; jamesrseibold{at}gmail.com
Citation
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
Publication history
- Received March 12, 2020
- Revised June 15, 2020
- Accepted June 29, 2020
- First published August 5, 2020.
Online issue publication
October 12, 2020
Article Versions
- Previous version (5 August 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.